Vancouver, January 18, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“Better Life” or “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), An emerging biotechnology company focused on developing and commercializing cutting-edge treatments for psychiatric disorders and viral infections announced that Health Canada has confirmed that 2-bromo-LSD is not a controlled drug. Did. According to Health Canada, “Information currently available at the Department of Controlled Drugs, 2-bromo-LSD, is not governed by the Schedule of Controlled Drugs and Substances Act.”
In the online version of Forbes magazine yesterday, Better Life CEO Ahmad Doroudian said that current regulations impose significant barriers to the development of current-generation psychedelic and LSD-based compounds and are uncontrolled, such as the TD-0148A. It further emphasized the benefits of the second generation psychedelics. ..You can access the full Forbes article here..
“Confirming the uncontrolled status of 2-bromo-LSD is an important first step for BetterLife to begin preclinical trials of its leading 2nd generation psychedelic product TD-0148A. During the development process of TD-0148A, we do not face significant regulatory hurdles that other psychedelic products must overcome. We can dispense at the pharmacy level and safely administer at home, We believe there is a great need for new non-psychedelic treatments for mental disorders. BetterLife’s TD-0148A is one such treatment, “said Ahmad Doroudian, CEO of BetterLife.BetterLife Pharma Inc.aboutBetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of next-generation psychedelic products for the treatment of mental illness. BetterLife leverages drug delivery platform technology to take drugs from a wide range of complementary interferon-based technologies that may involve the immune system to combat viral infections such as coronavirus disease (COVID-19) and human papillomavirus. We are improving and developing candidates. (HPV).
For more information,
please visit: www.abetterlifepharma.com
contact information:Ahmad Drudian, Chief executive officer
Email: Ahmad.Doroudian@blifepharma.com
Phone number: 604-221-0595
The stock exchange is not responsible for the validity or accuracy of the content of this news release. This news release contains forward-looking statements related to product development, licensing, commercialization, and regulatory compliance issues, as well as other statements that are not historical facts. Forward-looking statements are often identified by expressions such as “will,” “may,” “should,” “expect,” and “expect.” All statements other than the historical facts contained in this release are forward-looking statements with risks and uncertainties. There is no guarantee that such statements have been proven to be accurate and that actual results and future events may differ materially from those expected in such statements. Significant factors that may cause actual performance to differ materially from our expectations include non-compliance with relevant stock exchange requirements and other risks we will elaborate on from time to time when filing securities regulations. included. Readers should be aware that the assumptions used to create forward-looking information may turn out to be incorrect. As a result of many known and unknown risks, uncertainties, and other factors, the actual result may differ significantly from what was expected, depending on the event or situation. Readers should be careful not to overly rely on information about future prospects. Such information is considered reasonable by management at the time of its creation, but may prove inaccurate and actual results may differ materially from expectations. The forward-looking statements contained in this news release are explicitly modified by this notice. The forward-looking statements contained in this news release were made as of the date of this news release, and we have included forward-looking statements, as expressly required by applicable law. Publicly update or revise.
CBJ News Maker
BetterLife confirms unmanaged status of 2-bromo-LSD in Health Canada, Canada Business Journal
Source link BetterLife confirms unmanaged status of 2-bromo-LSD in Health Canada, Canada Business Journal
Related publications you might be interested in
